B+
Bull case
25%
Probability
Target price
$47.00
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
SNY
SanofiANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Q2 2026 sales grew 17.8% at constant exchange rates, Dupixent grew 37.6%, and business EPS grew 33.3%; Sanofi upgraded full-year guidance. Portfolio simplification may focus investment on higher-growth medicines [#PR-2026-07-30] [#PR-2026-09-14].
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.3.
What can break
Pipeline prioritization includes abandoned amlitelimab submission and discontinued itepikimab and balinatunfib programs; replacement R&D returns remain uncertain [#PR-2026-07-30].
Momentum
55
Value
68
Sentiment
54
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $41.50 · Bull $47.00 · Bear $34.00Analysis 2026-09-25; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $49.80
Why
Momentum55 · Δ7d -12.2
Value68 · Δ7d -0.3
Sentiment54 · Δ7d -2.5
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.3.
Contradictions & invalidation
- • Pipeline prioritization includes abandoned amlitelimab submission and discontinued itepikimab and balinatunfib programs; replacement R&D returns remain uncertain [#PR-2026-07-30].
- • Second-half growth normalization could expose dependence on Dupixent and recently acquired pharmaceutical launches [#PR-2026-07-30].
- • The Q2 release reported a 4.7% vaccines-sales decline, 17.9% higher R&D expense, and decisions not to advance amlitelimab to global submission or continue itepikimab and balinatunfib development.
Catalyst clock
2026-12-31
Delivery against upgraded 2026 guidance
Lead driver: Value · See fundamentals
Momentum
55
8% active weight
Current posture
7d trendSoftening
Δ7d
-12.2
Δ21d
+6.4
Value
68
47% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-0.9
Sentiment
54
45% active weight
Current posture
7d trendSoftening
Δ7d
-2.5
Δ21d
-11.9
Why this grade
Composite grade A. Momentum 55.4 / Value 68.5 / Sentiment 53.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-25. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$41.50
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$34.00
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$100.65B
Beta
0.43
Shares Out
2.38B
P/E (TTM)
16.1
P/S (TTM)
2.35
P/FCF (TTM)
97.54
Rev YoY
-7.0%
EPS YoY
+3.1%
Gross Margin
+66.3%
Op Margin
+27.2%
Net Debt
$14.86B
Current Ratio
0.99
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data